When is a shareholder announcement not a "Shareholder Announcement"?

31 January 2014

Sarah Wilson

EU regulation

Answer: when it's a selective mailing sent out to a privileged few under embargo before the formal announcement date.

Today we have the case of Novartis, which yesterday (Thursday, 30-Jan-14) faxed (yes, faxed) an advance copy of its AGM meeting notice to selected names on their share register ahead of the formal dispatch to ordinary shareholders.

In an era when notifications can be formally announced with a single mouse-click and simultaneously disseminated around the world, one wonders why a company would choose to deviate from its own articles of association by sending a meeting notice to a sub-set of their shareholders (and one of their providers) ahead of the formal dispatch day - potentially in violation of article 12 of their own articles of incorporation. Unfortunately, by so doing, there are unintended consequences which deserve highlighting.

It is likely there are thousands of Swiss shareholders who have no access to the meeting notice today (Friday, 31-Jan-14), whilst at the same time, some select global investors dotted around the world have it popping up on their PCs thanks to the custodian(s) and their ubiquitous appointed proxy distribution agent who have ignored the confidentiality of the announcement and disseminated it today anyway.

Perhaps most tragically, by disseminating the notice on a privileged access basis to the one provider with whom we understand Swiss issuers in particular have had most frustration in recent years, they are also perpetuating the problem they wish to solve - namely the dominance of a single provider in vote agency through whom practically everything must pass.

Also, there are other service providers (including Manifest) who have been put at a commercial disadvantage because, despite also having access to the notice, we have been told we are not allowed to put it up on our systems until Monday - formal dispatch day. We could have put it online anyway on the basis that it had been disclosed, but we thought we ought to check with the issuer first as a matter of courtesy. Novartis' insistence on "keeping to the deadline" seems pointless - another service provider has broken the embargo - and has, at time of writing, not taken the documents down (update 3rd February: the notice was in fact subsequently taken down over the weekend prior to dispatch date today, though of course after the damage was done).

This episode undermines the principle of fair access to information to the owners, in particular not discriminating against minority/retail shareholders. Having given the company a chance to rectify the situation by allowing us (and all other shareholders or service providers) formal access to the notice today, we are disappointed to report that all we can do at this point in time is write this blog piece highlighting the problem.

As for the systems and controls of the custodian(s) and their outsourced proxy vendor, we shall just have to wait and see if the FCA and other European regulators take proxy plumbing problems more seriously than they have done in previous years.

Latest News

SHareholder meeting

NA100 benchmark shows nature commitments progress as investors strengthen engagement efforts

SHareholder meeting

ESMA's Transition and Impact Claims Guidance: Lessons for SFDR II

SHareholder meeting

Tesla’s 2026 AGM sees no shareholder proposals for first time in over a decade

SHareholder meeting

Procter & Gamble shareholder rights proposals draw significant support

SHareholder meeting

Norway’s GPFG could ease nuclear weapons exclusions for allied defence companies

SHareholder meeting

IFRS Foundation reform: Can smaller IASB and ISSB boards preserve representation?

Featured Briefings

Minerva Briefing

US SEC Rule 14a-8 Rescission Proposal

Minerva Briefing

2026 Global Proxy Season Review

Minerva Briefing

Global IPOs: Growth, governance and risk

Minerva is a global provider of sustainable stewardship solutions with over 30 years of expertise. Minerva empowers investors by providing essential tools, including ESG research and data and expert insights, enabling them to navigate the intricate and ever-evolving landscape of stewardship and proxy voting, whilst ensuring their decisions are well-informed and aligned with sustainable principles.

Related Stories

Procter & Gamble shareholder rights proposals

Procter & Gamble shareholder rights proposals draw significant support

October 22, 2026
Read More
SFDR Review

SFDR review moves forward, but key questions remain for investors

September 11, 2026
Read More

Minerva Proxy Update

June 12, 2026
Read More
shareholder meetings and proxy voting

Minerva Proxy Update

June 5, 2026
Read More
Exon logo

ExxonMobil’s Texas redomicile passes with high dissent

June 5, 2026
Read More
AGM, Proxy Season, Shareholder Proposals

Minerva Proxy Update

May 29, 2026
Read More